520 related articles for article (PubMed ID: 24937198)
1. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
5. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
7. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
[TBL] [Abstract][Full Text] [Related]
8. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
9. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
10. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
11. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
Nguyen S; Gallay B; Butani L
Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
[TBL] [Abstract][Full Text] [Related]
13. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
[TBL] [Abstract][Full Text] [Related]
15. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.
Ticehurst EH; Molina MR; Frank R; Kearns J; Lal P; Goldberg LR; Tsai D; Wald J; Kamoun M
Clin Transpl; 2011; ():409-14. PubMed ID: 22755439
[TBL] [Abstract][Full Text] [Related]
17. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
18. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
[TBL] [Abstract][Full Text] [Related]
19. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
Fehr T; Gaspert A
Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
